Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset. “Nurix regularly reviews its operations to ensure we are effectively ...

Ginkgo Bioworks continues to face a weak demand environment, which has contributed to a lack of growth in recent years. Newer products and services have done little to change this situation, and it's ...

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean biosimilar specialist said it will throw down up to 700 billion Korean won ...

Monoclonal antibody (mAb) manufacturing must continually improve to keep up with increasing demands. To do this, biomanufacturers can deploy machine learning tools to augment traditional process ...

This article and associated images are based on a poster originally authored by Amy Turner, Poppy Nathan, Yanan Lu, Deepa Shankar, Danielle Callahan, Lion Lian and Jason Li and presented at ELRIG Drug ...

A number of blockbuster biologics worth $200 billion in revenue are expected to lose patent exclusivity by 2030 (1), which presents biosimilar manufacturers a huge opportunity for producing drugs at a ...

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first ...

IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...